Key result
Common single nucleotide polymorphisms at six loci (APOA1, APOE, LIPC, LPL, ANGPTL3, FADS1/2) demonstrate genotype-by-diet interactions that modulate lipid metabolism and cardiovascular disease risk.
Why the study?
Genomic testing for rare mutations has limited clinical utility due to scarcity, while common SNPs associated with CVD risk are increasingly accessible but lack demonstrated full clinical validity and evidence-supported management.
Common genetic variants in lipid metabolism pathways show potential for personalized dietary interventions to mitigate cardiovascular risk, though prospective validation is required before clinical implementation.
Answers are grounded in this paper and cite their sources.
These interactions may enable personalized dietary interventions; leaves open clinical adoption until validated in prospective trials.
Genomic testing for rare, highly penetrant cardiovascular pathogenic mutations is well established, but its scarcity limits broader clinical utility. As cardiogenomics matures, common single nucleotide polymorphisms (SNPs) associated with cardiovascular disease (CVD) risk are increasingly accessible to clinicians and patients through both clinician-ordered and direct-to-consumer (DTC) platforms. This narrative review synthesizes evidence for six common loci—APOA1, APOE, LIPC, LPL, ANGPTL3, and FADS1/2, here termed “candidate-actionable” in the limited sense that genotype-by-diet associations have been described, but the full chain of analytical validity, clinical validity, clinical utility, and evidence-supported management has not been demonstrated—that modulate lipid metabolism and CVD risk and that show genotype-by-diet interactions in observational and small interventional studies. We frame these loci as complementary to validated polygenic risk scores (PRSs), discuss two illustrative epistatic axes (APOE ε4 × FADS major T-allele; ANGPTL3 × LPL), summarize emerging epigenetic modulators of the same loci, and propose an integrated framework combining PRS, locus-level SNPs, and epigenetic state. All locus-specific dietary considerations are explicitly framed as hypothesis-generating pending validation in adequately powered, genotype-stratified prospective trials. A comparison of consumer and clinical testing platforms—updated to reflect recent ownership and regulatory changes—is provided.
No takes yet. Share an insight, caveat, or question.
Hands et al. (2026) conducted a review in Cardiovascular disease. Genotype-directed dietary interventions was evaluated. Common single nucleotide polymorphisms at six loci (APOA1, APOE, LIPC, LPL, ANGPTL3, FADS1/2) demonstrate genotype-by-diet interactions that modulate lipid metabolism and cardiovascular disease risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: